Navigation Links
Atrium Medical Receives FDA Approval for its Novel C-QUR Lite(TM) V-Patch and C-QUR Edge(TM) V-Patch
Date:5/8/2008

HUDSON, N.H., May 8 /PRNewswire/ -- Atrium Medical Corporation is pleased to announce it has obtained US FDA 510(K) approval for two new Omega 3 surgical mesh products; C-QUR Edge(TM) V-Patch and C-QUR Lite(TM) V-Patch.

These new products are indicated for use in the surgical repair and reinforcement of soft tissue, including hernia repair -- a common procedure performed more than 700,000 times in the US each year. This novel technology combines Atrium's ProLite Ultra(TM) polypropylene surgical mesh with a proprietary, pharmaceutical grade Omega 3 fatty acid bio-absorbable gel coating. Atrium's discovery of combining an inert thin wall polypropylene mesh with an Omega 3 biological coating in pre-clinical studies has demonstrated a minimization of tissue attachment as well as a significant reduction in both foreign body reaction and inflammation, resulting in a well healed, reinforced repair.

C-QUR Edge(TM) V-Patch and C-QUR Lite(TM) V-Patch are designed to simplify umbilical, epigastric, trocar-site, and other small abdominal wall hernia repairs. C-QUR Edge(TM) V-Patch offers long-term protection from visceral tissue attachment when placed intra-abdominally while the C-QUR Lite(TM) version offers superior handling and healing characteristics for a pre-peritoneal repair.

The use of Atrium's all natural Omega 3 bio-absorbable coating with its advanced lightweight surgical mesh provides today's clinicians with a broad spectrum of options for soft tissue repair. Atrium's C-QUR Edge(TM) V-Patch and C-QUR Lite(TM) V-Patch will be available in a variety of sizes mid-year 2008.

About Atrium

Atrium's vast expertise in medical device technologies for the treatment of cardiovascular disease, hernia and adhesion prevention has brought a number of breakthrough advances in several diversified healthcare markets including interventional cardiology and radiology, chest trauma care and thoracic drainage, vascular surgery, and soft tissue repair. Maintaining a commitment to the latest ISO13485 Quality Standards, state-of-the-art manufacturing and automation, cell biology and biomaterial discovery programs, Atrium continues to excel in those healthcare segments that require more advanced surgical intervention for improvements in patient outcome. For more information, call 800-370-7899 or visit http://www.atriummed.com.


'/>"/>
SOURCE Atrium Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Atrium Innovations Announces Management Changes
2. Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8
3. Atrium Announces a Significant Increase in Revenues and Earnings for the Third Quarter of 2007
4. Atrium Innovations to Hold 2007 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast on February 29
5. Atrium Innovations to Hold 2008 First Quarter Financial Results Conference Call and Webcast on May 6
6. Atrium shows a strong financial performance for its first quarter
7. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
8. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
9. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
10. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
11. BioMS Medical announces its intention to renew a normal course issuer bid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... , ... The recent vote by the American Medication Association to align with ... patients and hopefully sheds new light on the way health insurers, governments and the ... founding partner of Texas Fertility Center . , “This designation is something ...
(Date:6/27/2017)... ... 2017 , ... DuPont Pioneer (DuPont) and ERS Genomics (ERS) ... patent portfolio covering CRISPR-Cas genome editing technology for all agricultural uses and applications ... the CRISPR-Cas technology from co-inventor and co-owner Emmanuelle Charpentier, Ph.D. , “We ...
(Date:6/23/2017)... IA (PRWEB) , ... June 23, 2017 , ... Biova, ... Henig, Ph.D. has joined Biova’s Board of Directors. Dr. Henig will bring a wealth ... Dr. Henig has served as the Chief Technical and Scientific Officer of four major ...
(Date:6/22/2017)... ... June 21, 2017 , ... ... top executive talent in the life sciences industry, today announces a strategic partnership ... The partnership takes full advantage of Beaker’s expertise in executive recruitment solutions, providing ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):